<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03500289</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00164017</org_study_id>
    <nct_id>NCT03500289</nct_id>
  </id_info>
  <brief_title>Ketamine for Treatment of MS Fatigue</brief_title>
  <official_title>Ketamine for Treatment of Multiple Sclerosis-related Fatigue</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Multiple Sclerosis Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multiple sclerosis (MS) is an inflammatory, demyelinating and degenerative disease of the&#xD;
      central nervous system and, after trauma, is the most common cause of disability in young&#xD;
      adults, affecting more than 400,000 individuals in the US. Of all the symptoms that can occur&#xD;
      with MS, chronic fatigue is the most common and disabling, reported by at least 75% of&#xD;
      patients at some point. Fatigue limits patients' daily activities, and challenges employment,&#xD;
      resulting in substantial socioeconomic consequences. Despite this negative impact, fatigue&#xD;
      treatments have been inconsistently studied, in part due to poorly understood underlying&#xD;
      pathophysiological mechanisms. Yet to be defined biological processes and lack of clear&#xD;
      treatment targets have also hampered the development of drugs for fatigue. As a result, there&#xD;
      are no medications approved by the Food and Drug Administration (FDA) for the treatment of MS&#xD;
      fatigue.&#xD;
&#xD;
      The investigators recently reported that riluzole, a medication with anti-glutamatergic&#xD;
      effects, increased the fatigue severity in patients with relapsing MS who had participated in&#xD;
      a clinical trial evaluating potential neuroprotective effects of riluzole versus placebo.&#xD;
      Three other clinic trials which examined memantine effects on cognition in patient with MS&#xD;
      also reported worsening fatigue as a major side effect. Memantine main mechanism of action is&#xD;
      blocking the N-methyl D-aspartate (NMDA) glutamate receptor. These observations prompted the&#xD;
      investigators that glutamatergic transmission probably plays an important role in fatigue&#xD;
      pathogenesis and modulating these pathways could have potential therapeutic effect on&#xD;
      MS-related fatigue. A recent paper reported that ketamine, an NMDA receptor blocker with&#xD;
      different kinetics compared to memantine, had a strong and prolonged effect in reducing&#xD;
      fatigue in bipolar patients who participated in a clinical trial, evaluating anti-depressive&#xD;
      effects of ketamine versus placebo. Interestingly, the effect of ketamine on fatigue was&#xD;
      independent of its antidepressant effects.&#xD;
&#xD;
      The primary objective of this study is to determine if modulating glutamatergic transmission&#xD;
      with ketamine is safe and efficacious in improving MS-related fatigue. These objectives will&#xD;
      be answered in a proof of concept, randomized controlled trial of ketamine versus an active&#xD;
      placebo (midazolam) in patients with relapsing or progressive MS who have clinically&#xD;
      significant fatigue.&#xD;
&#xD;
      18 patients with MS and reported fatigue, will be randomized 2:1 to one infusion of ketamine&#xD;
      0.5 mg/kg over 40 minutes versus one infusion of midazolam 0.05 mg/kg over 40 minutes.&#xD;
      Midazolam is chosen as an active placebo to keep the participants blinded to participants'&#xD;
      medication assignment. Primary outcome of the study will be Daily Fatigue Severity measured&#xD;
      daily from day one through day seven post-infusion.&#xD;
&#xD;
      Secondary outcomes of the study include other fatigue questionnaires, depression and&#xD;
      sleepiness. The length of study will be around 28 days.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 10, 2018</start_date>
  <completion_date type="Actual">August 30, 2019</completion_date>
  <primary_completion_date type="Actual">August 30, 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Daily Fatigue Severity Score</measure>
    <time_frame>Baseline (infusion visit) through day 7</time_frame>
    <description>It is a single item question: 'how much fatigue (tiredness, weariness, problems thinking clearly) have you felt today?' with responses from 0 'None at all' to 10 'Extreme Fatigue'. Reported score changes are the average point/day score change. The mean score is reported based on this calculation: [(last day measure - baseline measure) / the number of days in the study].</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of Life in Neurological Disorders (NeuroQol) Fatigue Item Bank Score</measure>
    <time_frame>Baseline (infusion visit) through day 28 post-infusion</time_frame>
    <description>T-score distributions rescale raw scores into standardized scores with a mean of 50 and a standard deviation (SD) of 10. Higher T-scores denote more severe fatigue. Reported score changes are the average point/day score change. The mean score is reported based on this calculation: [(last day measure - baseline measure) / the number of days in the study].</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Modified Fatigue Impact Scale (MFIS) Score</measure>
    <time_frame>Baseline (infusion visit) through Day 28 post-infusion</time_frame>
    <description>The total score of the MFIS ranges from 0 to 84. Higher scores denote more severe fatigue. Reported score changes are the average point/day score change. The mean score is reported based on this calculation: [(last day measure - baseline measure) / the number of days in the study].</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Epworth Sleepiness Scale Score</measure>
    <time_frame>Baseline (infusion visit) through day 28 post-infusion</time_frame>
    <description>The Epworth Sleepiness Scale score can range from 0 to 24. The higher the score, the higher that person's average sleep propensity in daily life (ASP), or their 'daytime sleepiness'. Reported score changes are the average point/day score change. The mean score is reported based on this calculation: [(last day measure - baseline measure) / the number of days in the study].</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Beck Depression Inventory (BDI) Score</measure>
    <time_frame>Baseline (infusion visit) through day 28 post-infusion</time_frame>
    <description>The total score of the BDI ranges from 0 to 63. Higher scores denote more severe depressive symptoms. Reported score changes are the average point/day score change. The mean score is reported based on this calculation: [(last day measure - baseline measure) / the number of days in the study].</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Fatigue Severity Scale (FSS) Score</measure>
    <time_frame>Baseline (infusion visit) through day 28 post-infusion</time_frame>
    <description>The total score of the FSS ranges from 9 to 63. Higher scores denote more severe fatigue. Reported score changes are the average point/day score change. The mean score is reported based on this calculation: [(last day measure - baseline measure) / the number of days in the study].</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Multiple Sclerosis</condition>
  <condition>Fatigue</condition>
  <arm_group>
    <arm_group_label>Ketamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Midazolam</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine</intervention_name>
    <description>One intravenous infusion of ketamine 0.5 mg/kg over 40 minutes</description>
    <arm_group_label>Ketamine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam</intervention_name>
    <description>One intravenous infusion of midazolam 0.05 mg/kg over 40 minutes</description>
    <arm_group_label>Midazolam</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age between 18 years 65 years.&#xD;
&#xD;
          -  Females of childbearing age must have a negative urine pregnancy test at baseline and&#xD;
             use an effective method of contraception during the study.&#xD;
&#xD;
          -  Diagnosis of MS (according to the 2010 McDonald criteria).&#xD;
&#xD;
          -  Ambulatory (at least 20 feet using bilateral assistance).&#xD;
&#xD;
          -  Fatigue reportedly present and screening modified fatigue impact scale (MFIS) score&#xD;
             &gt;33.&#xD;
&#xD;
          -  Internet and email access and able to use a computer or tablet&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Beck Depression Inventory (BDI) score of more than 30.&#xD;
&#xD;
          -  Neurodegenerative disorders other than relapsing or progressive MS.&#xD;
&#xD;
          -  Breastfeeding or pregnant.&#xD;
&#xD;
          -  History of coronary artery disease or congestive heart failure.&#xD;
&#xD;
          -  Uncontrolled hypertension at screening (history of high blood pressure and screening&#xD;
             systolic blood pressure &gt;160 or diastolic blood pressure&gt;100).&#xD;
&#xD;
          -  History of severe liver disease, including cirrhosis.&#xD;
&#xD;
          -  Terminal medical conditions.&#xD;
&#xD;
          -  Currently treated for active malignancy.&#xD;
&#xD;
          -  Alcohol or substance abuse in the past year (except marijuana or other cannabinoids).&#xD;
&#xD;
          -  A history of intolerance or allergic or anaphylactic reaction to ketamine or midazolam&#xD;
&#xD;
          -  Clinically unstable medical or psychiatric disorders that require acute treatment as&#xD;
             determined by the PI.&#xD;
&#xD;
          -  History of severe or untreated coronary artery disease or history of congestive heart&#xD;
             failure.&#xD;
&#xD;
          -  History of prior ischemic or hemorrhagic stroke and cerebral vascular aneurysms.&#xD;
&#xD;
          -  History of recurrent seizures or epilepsy.&#xD;
&#xD;
          -  Taking any disallowed therapy(ies) as noted in Appendix 2 of the protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bardia Nourbakhsh, MD, MAS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>April 4, 2018</study_first_submitted>
  <study_first_submitted_qc>April 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 18, 2018</study_first_posted>
  <results_first_submitted>July 20, 2020</results_first_submitted>
  <results_first_submitted_qc>July 20, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">August 4, 2020</results_first_posted>
  <last_update_submitted>August 5, 2020</last_update_submitted>
  <last_update_submitted_qc>August 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Fatigue</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Midazolam</mesh_term>
    <mesh_term>Ketamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 6, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/89/NCT03500289/Prot_SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ketamine</title>
          <description>Ketamine: One intravenous infusion of ketamine 0.5 mg/kg over 40 minutes</description>
        </group>
        <group group_id="P2">
          <title>Midazolam</title>
          <description>Midazolam: One intravenous infusion of midazolam 0.05 mg/kg over 40 minutes</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ketamine</title>
          <description>Ketamine: One intravenous infusion of ketamine 0.5 mg/kg over 40 minutes</description>
        </group>
        <group group_id="B2">
          <title>Midazolam</title>
          <description>Midazolam: One intravenous infusion of midazolam 0.05 mg/kg over 40 minutes</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="18"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="12"/>
                    <count group_id="B2" value="6"/>
                    <count group_id="B3" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44" spread="12.4"/>
                    <measurement group_id="B2" value="49" spread="8.4"/>
                    <measurement group_id="B3" value="45.7" spread="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="12"/>
                    <count group_id="B2" value="6"/>
                    <count group_id="B3" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="12"/>
                    <count group_id="B2" value="6"/>
                    <count group_id="B3" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Daily Fatigue Severity Score</title>
        <description>It is a single item question: 'how much fatigue (tiredness, weariness, problems thinking clearly) have you felt today?' with responses from 0 'None at all' to 10 'Extreme Fatigue'. Reported score changes are the average point/day score change. The mean score is reported based on this calculation: [(last day measure - baseline measure) / the number of days in the study].</description>
        <time_frame>Baseline (infusion visit) through day 7</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketamine</title>
            <description>Ketamine: One intravenous infusion of ketamine 0.5 mg/kg over 40 minutes</description>
          </group>
          <group group_id="O2">
            <title>Midazolam</title>
            <description>Midazolam: One intravenous infusion of midazolam 0.05 mg/kg over 40 minutes</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Daily Fatigue Severity Score</title>
          <description>It is a single item question: 'how much fatigue (tiredness, weariness, problems thinking clearly) have you felt today?' with responses from 0 'None at all' to 10 'Extreme Fatigue'. Reported score changes are the average point/day score change. The mean score is reported based on this calculation: [(last day measure - baseline measure) / the number of days in the study].</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.05" lower_limit="-0.19" upper_limit="0.08"/>
                    <measurement group_id="O2" value="-0.05" lower_limit="-0.14" upper_limit="0.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Quality of Life in Neurological Disorders (NeuroQol) Fatigue Item Bank Score</title>
        <description>T-score distributions rescale raw scores into standardized scores with a mean of 50 and a standard deviation (SD) of 10. Higher T-scores denote more severe fatigue. Reported score changes are the average point/day score change. The mean score is reported based on this calculation: [(last day measure - baseline measure) / the number of days in the study].</description>
        <time_frame>Baseline (infusion visit) through day 28 post-infusion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketamine</title>
            <description>Ketamine: One intravenous infusion of ketamine 0.5 mg/kg over 40 minutes</description>
          </group>
          <group group_id="O2">
            <title>Midazolam</title>
            <description>Midazolam: One intravenous infusion of midazolam 0.05 mg/kg over 40 minutes</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Quality of Life in Neurological Disorders (NeuroQol) Fatigue Item Bank Score</title>
          <description>T-score distributions rescale raw scores into standardized scores with a mean of 50 and a standard deviation (SD) of 10. Higher T-scores denote more severe fatigue. Reported score changes are the average point/day score change. The mean score is reported based on this calculation: [(last day measure - baseline measure) / the number of days in the study].</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.02" lower_limit="-1.54" upper_limit="-0.5"/>
                    <measurement group_id="O2" value="-0.46" lower_limit="-1.20" upper_limit="0.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Modified Fatigue Impact Scale (MFIS) Score</title>
        <description>The total score of the MFIS ranges from 0 to 84. Higher scores denote more severe fatigue. Reported score changes are the average point/day score change. The mean score is reported based on this calculation: [(last day measure - baseline measure) / the number of days in the study].</description>
        <time_frame>Baseline (infusion visit) through Day 28 post-infusion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketamine</title>
            <description>Ketamine: One intravenous infusion of ketamine 0.5 mg/kg over 40 minutes</description>
          </group>
          <group group_id="O2">
            <title>Midazolam</title>
            <description>Midazolam: One intravenous infusion of midazolam 0.05 mg/kg over 40 minutes</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Modified Fatigue Impact Scale (MFIS) Score</title>
          <description>The total score of the MFIS ranges from 0 to 84. Higher scores denote more severe fatigue. Reported score changes are the average point/day score change. The mean score is reported based on this calculation: [(last day measure - baseline measure) / the number of days in the study].</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.46" lower_limit="-0.70" upper_limit="-0.23"/>
                    <measurement group_id="O2" value="0.02" lower_limit="-0.35" upper_limit="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Epworth Sleepiness Scale Score</title>
        <description>The Epworth Sleepiness Scale score can range from 0 to 24. The higher the score, the higher that person's average sleep propensity in daily life (ASP), or their 'daytime sleepiness'. Reported score changes are the average point/day score change. The mean score is reported based on this calculation: [(last day measure - baseline measure) / the number of days in the study].</description>
        <time_frame>Baseline (infusion visit) through day 28 post-infusion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketamine</title>
            <description>Ketamine: One intravenous infusion of ketamine 0.5 mg/kg over 40 minutes</description>
          </group>
          <group group_id="O2">
            <title>Midazolam</title>
            <description>Midazolam: One intravenous infusion of midazolam 0.05 mg/kg over 40 minutes</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Epworth Sleepiness Scale Score</title>
          <description>The Epworth Sleepiness Scale score can range from 0 to 24. The higher the score, the higher that person's average sleep propensity in daily life (ASP), or their 'daytime sleepiness'. Reported score changes are the average point/day score change. The mean score is reported based on this calculation: [(last day measure - baseline measure) / the number of days in the study].</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" lower_limit="-0.18" upper_limit="0.12"/>
                    <measurement group_id="O2" value="0.11" lower_limit="-0.11" upper_limit="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Beck Depression Inventory (BDI) Score</title>
        <description>The total score of the BDI ranges from 0 to 63. Higher scores denote more severe depressive symptoms. Reported score changes are the average point/day score change. The mean score is reported based on this calculation: [(last day measure - baseline measure) / the number of days in the study].</description>
        <time_frame>Baseline (infusion visit) through day 28 post-infusion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketamine</title>
            <description>Ketamine: One intravenous infusion of ketamine 0.5 mg/kg over 40 minutes</description>
          </group>
          <group group_id="O2">
            <title>Midazolam</title>
            <description>Midazolam: One intravenous infusion of midazolam 0.05 mg/kg over 40 minutes</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Beck Depression Inventory (BDI) Score</title>
          <description>The total score of the BDI ranges from 0 to 63. Higher scores denote more severe depressive symptoms. Reported score changes are the average point/day score change. The mean score is reported based on this calculation: [(last day measure - baseline measure) / the number of days in the study].</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.07" lower_limit="-0.25" upper_limit="0.11"/>
                    <measurement group_id="O2" value="0.07" lower_limit="-0.33" upper_limit="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Fatigue Severity Scale (FSS) Score</title>
        <description>The total score of the FSS ranges from 9 to 63. Higher scores denote more severe fatigue. Reported score changes are the average point/day score change. The mean score is reported based on this calculation: [(last day measure - baseline measure) / the number of days in the study].</description>
        <time_frame>Baseline (infusion visit) through day 28 post-infusion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketamine</title>
            <description>Ketamine: One intravenous infusion of ketamine 0.5 mg/kg over 40 minutes</description>
          </group>
          <group group_id="O2">
            <title>Midazolam</title>
            <description>Midazolam: One intravenous infusion of midazolam 0.05 mg/kg over 40 minutes</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Fatigue Severity Scale (FSS) Score</title>
          <description>The total score of the FSS ranges from 9 to 63. Higher scores denote more severe fatigue. Reported score changes are the average point/day score change. The mean score is reported based on this calculation: [(last day measure - baseline measure) / the number of days in the study].</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" lower_limit="-0.18" upper_limit="0.12"/>
                    <measurement group_id="O2" value="0.22" lower_limit="-0.11" upper_limit="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>One week</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Ketamine</title>
          <description>Ketamine: One intravenous infusion of ketamine 0.5 mg/kg over 40 minutes</description>
        </group>
        <group group_id="E2">
          <title>Midazolam</title>
          <description>Midazolam: One intravenous infusion of midazolam 0.05 mg/kg over 40 minutes</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Euphoria</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Bardia Nourbakhsh</name_or_title>
      <organization>Johns Hopkins University</organization>
      <phone>4106141522</phone>
      <email>bnourba1@jhmi.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

